Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy

International Journal of Clinical Pharmacy

Volumn 34, Issue 6, 2012, Pages 911-916

  Reina, Elena ^a   Miguel, Ramón San ^a   Larrea, Natalia ^a   Garcia, Patricia ^a   Napal, Victor ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

AIDS; Antiretrovirals; Boosted protease inhibitors; HIV infection; Monotherapy

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; COST CONTROL; DRUG COST; DRUG DOSE REGIMEN; FEMALE; HEALTH CARE COST; HEALTH IMPACT ASSESSMENT; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL PHARMACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROLOGIC DISEASE; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPAIN; TREATMENT DURATION; VIROLOGY; VIRUS LOAD;

ADULT; AMBULATORY CARE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST SAVINGS; DRUG COSTS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PHARMACY SERVICE, HOSPITAL; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SPAIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872178376     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9692-5     Document Type: Article

References (30)

1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012. http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed 2 Apr 2012.
2. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-33.
3. European AIDS Clinical Society (EACS). European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. 2011. http://www.euro peanaidsclinicalsociety.org/index.php?option=com- content&view= article&id=59:eacs-guidelines&catid=37: guidelines&Itemid=41. Accessed 2 Apr 2012.
4. Spanish AIDS Study Group (GESIDA) and the National AIDS Plan. National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus. 2012. http://www.gesida- seimc.org/ pcientifica/fuentes/DcyRc/gesidadcyrc2012-Documentoconsenso-TAR- adulto-verordenador.pdf. Accessed 2 Apr 2012.
5. Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24(2):223-30.
6. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: A randomized open-label, noninferiority trial, MONOIANRS 136. AIDS. 2010;24(15):2365-74.
7. Arribas JR, Delgado R, Arranz A, Munoz R, Portilla J, Pasquau J, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009;51(2):147-52.
8. Pulido F, Matarranz M, Rodriguez-Rivera V, Fiorante S, Hernando A. Boosted protease inhibitor monotherapy. What have we learnt after seven years of research? AIDS Rev. 2010;12(3):127-34. Epub 2010/09/16.
9. Pulido Ortega F, Llenas-Garcia J. Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection. Enferm Infecc Microbiol Clin. 2008;26(Suppl 16): 12-20. Epub 2009/07/03.
10. Valencia-Ortega ME, Moreno-Celda V. From research to clinical practice: Use of lopinavir/ritonavir in monotherapy. Enferm Infecc Microbiol Clin. 2008;26(10):671-2.
11. Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice. J Antimicrob Chemother. 2007;60(2): 436-9. (Pubitemid 47243902)
12. Pierone G, Mieras J, Bulgin-Coleman D, Kantor C, Shearer J, Fontaine L, et al. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials. 2006;7(5):237-45. (Pubitemid 44963807)
13. Gonza'lez Rivas L, Sa'nchez Go'mez E, Sa'nchez del Moral R, Grutzmancher Saiz S, Pujol de la Llave E, Bocanegra Marti'n C. Simplification of antiretroviral therapy: A good choice for our patients and the sustainability of our health care system. Farm Hosp. 2011;35(6):317-21.
14. Sahali S, Chaix ML, Delfraissy JF, Ghosn J. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev. 2008;10(1):4-14. (Pubitemid 351524047)
15. Nunes EP, Santini de Oliveira M, Merçon M, Zajdenverg R, Faulhaber JC, Pilotto JH, et al. Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: Results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials. 2009;10(6):368-74.
16. Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, et al. Longterm (96-week) follow-up of antiretroviral-nai?ve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med. 2010;11(2): 137-42.
17. Pulido F, Serrano O, Rivero A. Atazanavir/ritonavir monotherapy for maintenance of virologic suppression: 48 week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY Study. In: Gazzard B, Lundgren J, editors. Abstracts of the 12th European AIDS conference/EACS, 11-14 Nov 2009, Cologne. HIV Med. 2009;10(Suppl 2):1-246.
18. Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296(7):806-14. (Pubitemid 44223104)
19. Knobel H, Escobar I, Polo R, Ortega L, Marti'n-Conde MT, Casado JL, et al. Recommendations from GESIDA/SEFH/PNS to improve adherence to antiviral treatment (2004). Enferm Infecc Microbiol Clin. 2005;23(4):221-31. (Pubitemid 40562586)
20. Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, et al. Prognostic factors for virological response in antiretroviral therapy-nai?ve patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone. Antivir Ther. 2009;14(1): 93-7.
21. Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, et al. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. AIDS Res Hum Retroviruses. 2009;25(3):269-75.
22. Ibarra Barrueta O, Ortega Vali'n L, Grupo VIH de la SEFH. Survey of the pharmaceutical care situation of the HIV patient in Spain. Farm Hosp. 2008;32(3):170-7.
23. Inciardi JF, Leeds AL. Assessing the utility of a community pharmacy refill record as a measure of adherence and viral load response in patients infected with human immunodeficiency virus. Pharmacotherapy. 2005;25(6):790-6. (Pubitemid 40727129)
24. Alberts B. Science breakthroughs. Science. 2011;334(6063):1604.
25. Friis-Møller N, Weber R, Reiss P, Thie'baut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-93. (Pubitemid 36667761)
26. Saez de la Fuente J, Such Di'az A, Sa'nchez Gil C, Esteban Alba C, Escobar Rodri'guez I. Meta-analysis of the effectiveness of the strategy of monotherapy with boosted protease inhibitors in HIV? patients. Farm Hosp. 2010;34(5):251-8.
27. Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: A meta-analysis. PLoS ONE. 2011;6(7):e22003.
28. Perez-Valero I, Arribas Jr. Protease inhibitor monotherapy. Curr Opin Infect Dis. 2011;24(1):7-11. Epub 2010/12/15.
29. Arribas JR, Pulido F, Lázaro P, Méndez I. Estudio farmacoecono ́mico de lopinavir/ritonavir en monoterapia en el ensayo clínico OK04. PharmacoEconomics-Spanish Research Articles. 2011;8(3):85-97.
30. Pasquau J, Gostkorzewicz J, Ledesma F, Anceau A, Hill A, Moecklinghoff C. Budget impact analysis of switching to darunavir/ ritonavir monotherapy for HIV-infected people in Spain. Appl Health Econ Health Policy. 2012;10(2):139-41.